Gritstone Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gritstone Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the Compensation Committee of the company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 6,850 shares of its common stock with an exercise price of $0.75, which is equal to the closing price of Gritstone's common stock on June 7, 2024, the date of the grant. These stock options are part of an inducement material to the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年6月13日，加州埃默瑞維爾，全球新聞社——gritstone bio, Inc.（納斯達克：GRTS），一家旨在開發世界上最有效的疫苗的臨床生物技術公司，今天宣佈公司董事會的報酬委員會授予一名員工非合格股票期權，購買6,850股其普通股，行權價爲0.75美元，等於gritstone普通股於2024年6月7日收盤價，即授予日的收盤價。這些股票期權是根據納斯達克規則5635(c)(4)的規定，是成爲gritstone新僱員的重要激勵措施。
The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees' date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees' continued employment with Gritstone on such vesting dates. The stock options are subject to the terms and conditions of Gritstone's 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
這些股票期權將在四年內分期歸屬，其中，25%的期權將在員工入職紀念日第一年歸屬，之後每月歸屬1/48，但前提是員工在歸屬日期繼續在gritstone任職。股票期權受gritstone的2021年就業激勵獎勵計劃和授予股票期權的協議的條款和條件約束。
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world's most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
關於gritstone bio
Gritstone bio公司（納斯達克：GRTS）是一家臨床階段的生物技術公司，旨在開發全球最強效的疫苗。我們利用創新的載體和負載來訓練多個免疫系統去攻擊重要的疾病目標。獨立和與我們的合作伙伴一起，我們正在推進一系列治療和預防病毒性疾病和實體腫瘤的產品候選方案，以追求改善患者預後和消除疾病。www.gritstonebio.com
Gritstone bio Contacts
Investors:
George E. MacDougall
Gritstone bio, Inc.
ir@gritstone.com
gritstone bio 聯繫方式
投資者：
George E. MacDougall
gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
媒體：
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
譯文內容由第三人軟體翻譯。